NCT02032810View on ClinicalTrials.gov

Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

January 7, 2014

Primary Completion Date

September 6, 2017

Study Completion Date

September 25, 2019

Conditions
MelanomaSkin Cancer
Interventions
DRUG

Panobinostat

Participants will be assigned to receive a certain dose of panobinostat (5, 10, 15, or 20 mg). The dose of panobinostat will depend on the time point the participant enters the study and the side effects of other participants already on the study.

DRUG

Ipilimumab

Dose of ipilimumab of 3 mg per kg (mg/kg) of body weight.

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center and Research Institute, Tampa

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER